Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

被引：29

作者：

Socinski, M. A. ^{[1
]}

机构：

[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA

来源：

CURRENT ONCOLOGY | 2014年 / 21卷 / 05期

关键词：

Docetaxel; elderly patients; nab-paclitaxel; paclitaxel; squamous cell carcinoma; PHASE-III TRIAL; PACLITAXEL PLUS CARBOPLATIN; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; SOUTHWEST-ONCOLOGY-GROUP; WEEKLY NAB-PACLITAXEL; ELDERLY-PATIENTS; RANDOMIZED-TRIAL; MULTICENTER TRIAL; COMBINATION CHEMOTHERAPY;

D O I：

10.3747/co.21.1997

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Based on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-small-cell lung cancer (NSCLC) and NSCLC subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic NSCLC. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxel-carboplatin in a phase III trial. This review focuses on the evolution of first-line taxane therapy for advanced NSCLC and the new options and advances in taxane therapy that might address unmet needs in advanced NSCLC.

引用

页码：E691 / E703

页数：13

共 50 条

[1] First-line treatment for advanced non-small-cell lung cancer
Laskin, Janessa J.
Sandler, Alan B.
ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
[2] Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer
Heigener, David F.
Kerr, Keith M.
Laing, Gavin M.
Mok, Tony S. K.
Moiseyenko, Fedor V.
Reck, Martin
CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4881 - 4887
[3] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Gettinger, Scott
Rizvi, Naiyer A.
Chow, Laura Q.
Borghaei, Hossein
Brahmer, Julie
Ready, Neal
Gerber, David E.
Shepherd, Frances A.
Antonia, Scott
Goldman, JonathanW.
Juergens, Rosalyn A.
Laurie, Scott A.
Nathan, Faith E.
Shen, Yun
Harbison, Christopher T.
Hellmann, Matthew D.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
[4] First-line immunotherapy in advanced non-small-cell lung cancer
Noronha, Vanita
Mehta, Prashant
Malik, Prabhat Singh
Patel, Amol
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
[5] Erlotinib in the first-line treatment of non-small-cell lung cancer
D'Arcangelo, Manolo
Cappuzzo, Federico
EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
[6] First-line treatment of advanced ALK-positive non-small-cell lung cancer
Gandhi, Shipra
Chen, Hongbin
Zhao, Yujie
Dy, Grace K.
LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
[7] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
Liam, Chong-Kin
TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
[8] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Kao, Hsiang-Fong
Lin, Chia-Chi
Yang, James Chih-Hsin
FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
[9] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
Raez, Luis E.
Kobina, Svetlana
Santos, Edgardo S.
CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
[10] Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
Laktionov, K.
Smolin, A.
Stroyakovskiy, D.
Moiseenko, V.
Dvorkin, M.
Andabekov, T.
Cheng, Y.
Liu, B.
Kozlov, V.
Odintsova, S.
Dvoretsky, S.
Mochalova, A.
Urda, M.
Yi, T.
Li, X.
Laszlo, U.
Mueller, V.
Bogos, K.
Fadeeva, N.
Musaev, G.
Liu, Q.
Kirtbaya, D.
Shi, J.
Gladkov, O.
Narimanov, M.
Semiglazova, T.
Khasanova, A.
Chovanec, J.
Andrasina, I
Szabova, A.
Rosinska, O.
Sudekova, D.
Zsolt, P. -s.
Ran, F.
Sun, M.
Jiang, O.
Chen, R.
Zhao, E.
Liu, C.
Tan, W.
Pirmagomedov, A.
Poddubskaya, E.
Kislov, N.
Shumskaya, I.
Sorokina, I.
Zinkina-Orikhan, A.
Linkova, Yu.
Fogt, S.
Liaptseva, D.
Siliutina, A.
EUROPEAN JOURNAL OF CANCER, 2025, 217

← 1 2 3 4 5 →